Get To Know Severe Asthma: The Chronic, Life-Threatening Condition Affecting 7-11% Adults In Asian Countries
KUALA LUMPUR, Malaysia, Sept. 25, 2024 /PRNewswire/ -- Asthma is well-known as a common respiratory condition. But did you know that there exists a life-threatening type of the condition called severe asthma, that requires specialised, multidisciplinary treatment to manage? Severe asthma is estimated to affect 7% to 11% of adults in Asian countries, while worldwide the condition affects 3%-10%...
Amaran Biotech Makes Its Debut at BioJapan 2024 in Yokohama
HSINCHU, Sept. 25, 2024 /PRNewswire/ -- Amaran Biotech, a leading Taiwanese CDMO (Contract Development & Manufacturing Organization) offering comprehensive pharmaceutical development and manufacturing solutions, will debut at BioJapan 2024 in Yokohama from October 9-11. The company is participating as part of Taiwan's Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) delegation. Amaran Biotech will showcase its services at the Taiwan...
G7 DFIs, MedAccess, EIB, and IFC Announce MoU for Surge Financing Initiative for Medical Countermeasures
Media Kit: DFC at UNGA 2024 NEW YORK, Sept. 25, 2024 /PRNewswire/ -- Today, participating G7 development finance institutions (DFIs), MedAccess, the European Investment Bank (EIB), and the International Finance Corporation (IFC) announced the signing of a memorandum of understanding (MoU) for the Surge Financing Initiative for Medical Countermeasures (MCMs). These DFIs are...
EADV Congress 2024: Semaglutide improves outcomes for obese patients with common skin condition, new study shows
A pioneering study, presented today at the EADV Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic skin condition, in people with obesity. AMSTERDAM, Sept. 25, 2024 /PRNewswire/ -- This is the first study to explore the use of semaglutide for HS, marking a critical milestone in the search for effective treatments...
Everise Signs Agreement to Acquire Continuum Global Solutions’ Healthcare Vertical
The acquisition strengthens the foundation for Everise as an end-to-end healthcare experience provider PLANTATION, Fla., Sept. 25, 2024 /PRNewswire/ -- Global healthcare customer experience company Everise today announced that it has signed a binding agreement to acquire the healthcare vertical of Continuum Global Solutions (CGS), a customer services management company, from Skyview Capital....
EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment
ADELAIDE, South Australia, Sept. 24, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with drug developer EnGeneIC Pty Ltd., for a project including technology transfer, process scale-up and GMP batch manufacture of EnGeneIC's proprietary 'EnGeneIC Dream Vector' (EDV™) nanocells. EnGeneIC's mission is...
LongBio announced the completion of Series B2 financing, led by Qiming Venture Partners
SHANGHAI, Sept. 24, 2024 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio" or the "Company"), a Phase III-stage biotech company focused on the R&D of innovative antibody and fusion protein drugs for allergies and complement-mediated diseases, announced the completion of its Series B2 financing round, raising tens of millions of RMB. The round was led by Qiming Venture Partners,...
XtalPi Launches Computational Chemistry Software for Drug Discovery: XMolGen and XFEP
BOSTON and SHANGHAI, Sept. 24, 2024 /PRNewswire/ -- Today, XtalPi announced the official launch of XFEP and XMolGen, two proprietary software products designed to accelerate and enhance the efficiency of drug discovery. Upon this launch, XtalPi will offer commercial licenses with flexible terms for industrial and academic scientists to use the...
Noul Demonstrates ‘Expert-Level’ AI Diagnostic Performance in Europe… Results from Spain’s Carlos III Health Institute
Study of 329 Patients in Europe Shows Superior Performance Compared to Microscopic Diagnosis Sensitivity: 94.4%, Specificity: 97.2%, Agreement Rate: 92% YONGIN, South Korea, Sept. 24, 2024 /PRNewswire/ -- Noul Co., Ltd. (CEO: David Lim, hereafter referred to as "Noul") has proven the expert-level diagnostic performance of its AI in Europe. Noul...
Bestqool Pro Series Iteration: Upgraded Design for Enhanced User Experience
NEW YORK, Sept. 24, 2024 /PRNewswire/ -- Bestqool, a leading red light therapy industry company, proudly presents the newest iteration of its Pro Series line. It features advanced design improvements and multiple upgraded functionalities for optimum performance. This launch represents the next-generation leap in professional red light treatment technology by enhancing user experience and therapeutic benefits. Behind this Pro Series...
